JOP20150154B1 - صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها - Google Patents
صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرهاInfo
- Publication number
- JOP20150154B1 JOP20150154B1 JOP/2015/0154A JOP20150154A JOP20150154B1 JO P20150154 B1 JOP20150154 B1 JO P20150154B1 JO P20150154 A JOP20150154 A JO P20150154A JO P20150154 B1 JOP20150154 B1 JO P20150154B1
- Authority
- JO
- Jordan
- Prior art keywords
- ezetimibe
- rosuvastatin
- oral administration
- preparation
- composite formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
- 229960000672 rosuvastatin Drugs 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title abstract 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 2
- 229960000815 ezetimibe Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 239000008187 granular material Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير صيغة مادة مركبة صلبة للإعطاء عن طريق الفم والتي تتضمن: جزء من حبيبة رطبة-إزيتمايب بما في ذلك إزيتمايب الذي يكون رطب-محبب باستخدام وسيلة تحبيب طبقة-مائع؛ وجزء خليط من رسيوفاستاتين بما في ذلك رسيوفاستاتين أو ملح منه مقبول صيدلانيا.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140078388A KR101977785B1 (ko) | 2014-06-25 | 2014-06-25 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20150154B1 true JOP20150154B1 (ar) | 2021-08-17 |
Family
ID=54938391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2015/0154A JOP20150154B1 (ar) | 2014-06-25 | 2015-06-24 | صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها |
Country Status (10)
| Country | Link |
|---|---|
| KR (1) | KR101977785B1 (ar) |
| AR (1) | AR100977A1 (ar) |
| BR (1) | BR112016030111A2 (ar) |
| CL (1) | CL2016003283A1 (ar) |
| EC (1) | ECSP16096477A (ar) |
| JO (1) | JOP20150154B1 (ar) |
| SG (2) | SG10201811586YA (ar) |
| TW (1) | TWI700100B (ar) |
| UY (1) | UY36190A (ar) |
| WO (1) | WO2015199356A1 (ar) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2016539A3 (cs) * | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
| CZ2016538A3 (cs) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky |
| KR102206535B1 (ko) * | 2016-11-29 | 2021-01-22 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 |
| EP3437636A1 (en) * | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
| KR102500643B1 (ko) * | 2019-04-18 | 2023-02-16 | 한미약품 주식회사 | 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제 |
| KR20200137243A (ko) | 2019-05-29 | 2020-12-09 | 콜마파마(주) | 로수바스타틴 및 에제티미브를 포함하는 복합제의 제조방법 |
| BR112022001783A2 (pt) | 2019-07-31 | 2022-03-22 | Tecnimede Sociedade Tecnico Medicinal Sa | Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos. |
| BR112023003323A2 (pt) * | 2020-08-25 | 2023-03-21 | Daewoong Pharmaceutical Co Ltd | Composição farmacêutica em forma de dosagem única |
| KR20250096941A (ko) | 2023-12-20 | 2025-06-30 | 안국약품 주식회사 | 피타바스타틴 및 에제티미브를 포함하는 단일 정제 형태의 약학 조성물 및 이의 제조방법 |
| KR20250161310A (ko) * | 2024-05-08 | 2025-11-17 | 한미약품 주식회사 | 복약순응도가 개선된 에제티미브, 로수바스타틴 및 엠파글리플로진을 포함하는 복합제제 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100907144B1 (ko) * | 2007-09-05 | 2009-07-09 | 박재섭 | 이동부재를 이용한 골프 클럽 |
| WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2448919A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| HUE038048T2 (hu) * | 2009-07-28 | 2018-09-28 | Egyt Gyogyszervegyeszeti Gyar | Új granulálási eljárás és ezzel elõállított granulátum |
| EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| MX365046B (es) * | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares. |
-
2014
- 2014-06-25 KR KR1020140078388A patent/KR101977785B1/ko active Active
-
2015
- 2015-06-09 SG SG10201811586YA patent/SG10201811586YA/en unknown
- 2015-06-09 WO PCT/KR2015/005779 patent/WO2015199356A1/en not_active Ceased
- 2015-06-09 BR BR112016030111A patent/BR112016030111A2/pt not_active Application Discontinuation
- 2015-06-09 SG SG11201610748RA patent/SG11201610748RA/en unknown
- 2015-06-16 TW TW104119406A patent/TWI700100B/zh active
- 2015-06-24 AR ARP150102016A patent/AR100977A1/es not_active Application Discontinuation
- 2015-06-24 JO JOP/2015/0154A patent/JOP20150154B1/ar active
- 2015-06-24 UY UY0001036190A patent/UY36190A/es not_active Application Discontinuation
-
2016
- 2016-12-21 CL CL2016003283A patent/CL2016003283A1/es unknown
- 2016-12-23 EC ECIEPI201696477A patent/ECSP16096477A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201625223A (zh) | 2016-07-16 |
| CL2016003283A1 (es) | 2017-07-28 |
| SG10201811586YA (en) | 2019-02-27 |
| BR112016030111A2 (pt) | 2017-08-22 |
| WO2015199356A1 (en) | 2015-12-30 |
| UY36190A (es) | 2015-10-30 |
| KR101977785B1 (ko) | 2019-05-14 |
| SG11201610748RA (en) | 2017-01-27 |
| ECSP16096477A (es) | 2017-01-31 |
| AR100977A1 (es) | 2016-11-16 |
| KR20160000762A (ko) | 2016-01-05 |
| TWI700100B (zh) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20150154B1 (ar) | صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها | |
| MY187637A (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| EP4527467A3 (en) | Pharmaceutical formulations | |
| SG10201902598VA (en) | Peptidomimetic macrocycles and formulations thereof | |
| EP3173412A4 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| PH12017502376B1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| MX2017016802A (es) | Formulaciones farmaceuticas. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| EP4342461A3 (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| IL262204A (en) | Granular formulation for oral administration | |
| SG11201912827TA (en) | 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof | |
| TR201722603A2 (tr) | Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari | |
| WO2018119108A8 (en) | Solid pharmaceutical formulations of asimadoline | |
| PH12016502540B1 (en) | Pharmaceutical dosage forms | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| HK40000168A (en) | Granule formulation for oral administration | |
| AU2017900496A0 (en) | Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin | |
| HK1233927A1 (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| HK1243323A1 (zh) | 使用赤式羟基安非他酮调节药物血浆水平的方法 |